Ocrevus (ocrelizumab), Roche’s FDA-approved multiple sclerosis (MS) antibody, demonstrated hints of disease modification and cognitive benefit in phase 3b data that will be presented at the annual meeting of the American Academy of Neurology (AAN).
Source: Drug Industry Daily